On this page

CMS RVU26D · Effective 2026-10-01

G2082 Esketamine visit Medicare reimbursement rates in Indiana

Report this established-patient visit for supervised esketamine treatment of up to 56 mg, including the required post-dose observation period. Compare G2082 office and facility rates across CMS payment localities in Indiana.

Amounts below use the non-QP conversion factor for participating physicians. These are base physician payments before claim-level adjustments, not patient costs or total hospital charges.

What does Medicare pay for G2082 in Indiana?

Indiana has 1 payment locality in this comparison. Use the service location to choose the applicable amount. These are the supported base rates for the payment area shown below, using the same CMS release.

Office / nonfacility

$883.73

1 of 1 localities have a supported rate.

Payment area: Indiana

One mapped payment locality.

Facility setting

$29.47

1 of 1 localities have a supported rate.

Payment area: Indiana

One mapped payment locality.

These are locality ranges, not averages or address-specific quotes. A facility-setting amount covers the physician service; it does not include a hospital’s separate bill. Choose a locality below to inspect its calculation, compare other payment areas, or price a percentage of Medicare.

Find G2082 in your payment locality →

Behavioral health

About G2082: Esketamine treatment visit, up to 56 mg

Report this established-patient visit for supervised esketamine treatment of up to 56 mg, including the required post-dose observation period.

G2082 covers an established-patient outpatient visit for supervised esketamine treatment when the dose is 56 mg or less. It includes the evaluation and management associated with the treatment, provision of the medication, and two hours of post-administration observation. The patient self-administers intranasal esketamine under the supervision of a qualified clinician, commonly in an outpatient behavioral health or psychiatric setting. Treatment is used for conditions such as treatment-resistant depression.

Select G2082 by the esketamine dose for the visit, not by the number of minutes spent with the clinician: 56 mg is included, while a higher dose points to G2083. Document the dose provided, the supervised treatment, and the observation. The code packages the visit, medication, and observation together; do not unbundle those elements as separate services under this code. CMS assigns different practice-expense inputs for office and facility settings.

Where the value comes from

  • Work RVU0.70 · 2%
  • Practice expense (office) RVU27.75 · 97%
  • Malpractice RVU0.07 · 0%

4.5K

Medicare services in 2024 · #1950 by national volume

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

G2082 compared with similar codes

Office rates for Indiana, from the same CMS release.

G2083

Esketamine visit

Dose over 56 mg

$1,257.76

Both codes cover supervised esketamine treatment with two hours of post-dose observation. Choose G2082 for doses up to and including 56 mg; choose G2083 for doses above 56 mg.

99213

Office visit

Established patient, low complexity

$90.09

99213 describes a separately selected established-patient E/M service. G2082 is specific to the bundled esketamine visit, medication, and observation, so it is not selected based on an E/M level.

Compare G2082 by payment locality

Find the payment area for your service address, then open its rate page for calculation inputs, release history and the percentage-of-Medicare tool. A city may cross payment-area boundaries; the ZIP lookup above helps resolve the location.

1 of 1 payment localities

Office and facility base rates · shared scale starting at $0

Need rates for a whole code list?

Fee-sheet and API access are in early access. Tell us which codes and locations your team needs.

Explore fee-sheet early access →

How this local rate is calculated

Each RVU component is multiplied by its own geographic practice cost index (GPCI). The three adjusted components are added, then multiplied by the conversion factor. These are the inputs used for G2082 in Indiana.

PPRRVU2026_Oct_nonQPP.csv

15,439

Code
G2082
Physician work
0.70
Practice expense
27.75
Malpractice
0.07

GPCI2026.csv

52

Locality
Indiana
Physician work
1.000
Practice expense
0.927
Malpractice
0.486
Office / nonfacility calculation for G2082 in Indiana
ComponentRVULocality factorAdjusted
Physician work0.70× 1.0000.7000
Practice expense27.75× 0.92725.7243
Malpractice0.07× 0.4860.0340
Total RVUs26.4583
Conversion factor× 33.4009

Office / nonfacility rate, Indiana$883.73

Explore RVUs, geographic factors and the full formula

Office / nonfacility

Office / nonfacility calculation inputs
ComponentRVULocal GPCI
Work0.71
Practice expense27.750.927
Malpractice0.070.486

(0.7 × 1 + 27.75 × 0.927 + 0.07 × 0.486) × $33.4009 = $883.73

Facility

Facility calculation inputs
ComponentRVULocal GPCI
Work0.71
Practice expense0.160.927
Malpractice0.070.486

(0.7 × 1 + 0.16 × 0.927 + 0.07 × 0.486) × $33.4009 = $29.47

The office and facility calculations use their respective practice-expense RVUs. The facility amount here is the physician fee, not a separate hospital or facility bill.

G2082 billing questions

How do I choose between G2082 and G2083?

Use G2082 when the esketamine dose is 56 mg or less. G2083 is for a dose greater than 56 mg.

Does the 56-minute limit refer to visit time?

No. The 56 mg threshold is the esketamine dose, not the duration of the visit.

Does G2082 include the medication and observation?

Yes. The code includes provision of the esketamine and two hours of post-administration observation, along with the associated established-patient visit.

What documentation supports G2082?

Document the esketamine dose, the supervised treatment, and the post-dose observation. The record should support that the visit involved esketamine treatment rather than a routine office evaluation alone.

Can I report a separate office E/M service for the same treatment visit?

G2082 already includes the associated evaluation and management for the esketamine treatment. Do not report a separate E/M code for those same bundled services.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense, and malpractice RVUs, adjusted by each locality’s geographic indices and the applicable conversion factor. Unavailable or separately priced services are labeled rather than assigned a made-up amount.

Source: RVU26D. Effective 2026-10-01 through the day before 2027-01-01.

RVUs for G2082PPRRVU2026_Oct_nonQPP.csv, line 15,439 (RVU26D)
Geographic factors for IndianaGPCI2026.csv, line 52 (RVU26D)